摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5,5-dimethyl-5H-thieno<3,2-b>pyran | 129969-32-0

中文名称
——
中文别名
——
英文名称
5,5-dimethyl-5H-thieno<3,2-b>pyran
英文别名
5,5-dimethyl-5H-thieno[3,2-b]pyran;5,5-dimethylthieno[3,2-b]pyran
5,5-dimethyl-5H-thieno<3,2-b>pyran化学式
CAS
129969-32-0
化学式
C9H10OS
mdl
MFCD28362790
分子量
166.244
InChiKey
JIVGFTRLLYSYQT-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    236.8±29.0 °C(Predicted)
  • 密度:
    1.119±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.6
  • 重原子数:
    11
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.333
  • 拓扑面积:
    37.5
  • 氢给体数:
    0
  • 氢受体数:
    2

反应信息

  • 作为反应物:
    参考文献:
    名称:
    Thiophene systems. 14. Synthesis and antihypertensive activity of novel 7-(cyclic amido)-6-hydroxythieno[3,2-b]pyrans and related compounds as new potassium channel activators
    摘要:
    The synthesis and antihypertensive activity of novel 7-(cyclic amido)-6-hydroxy-5,5-di-methylthieno[3,2-b]pyrans and related compounds are described. The compounds were tested for oral antihypertensive activity in spontaneously hypertensive rats (SHR) and selected compounds were evaluated in vitro for increases in Rb-86 efflux in rabbit isolated mesenteric arteries. The effects on activity in SHR of lactam ring size, the presence of heteroatoms in the lactam ring, the relative stereochemistry at C-6 and C-7, and the substituents on the thiophene ring are examined. The best racemic compound in this series is 32, trans-5,6-dihydro-6-hydroxy-5,5-di-methyl-2-nitro-7-(2-oxopiperidin-1-yl)-5H-thieno[3,2-b]pyran, which is 10-fold more potent than cromakalim with an ED30 = 0.015 mg/kg in SHR. Compound 32 could be resolved and the antihypertensive activity determined to reside primarily in the (6S,7S)-(-)-enantiomer 41. Surprisingly, the elimination of water to give the enamides 50-52, thiophene isosteres of bimakalim, diminishes activity significantly.
    DOI:
    10.1021/jm00101a020
  • 作为产物:
    参考文献:
    名称:
    Thienopyran derivatives, their use for treating hypertension and asthma
    摘要:
    通式为##STR1## 的噻吩并吡喃衍生物,其中径向##STR2## 表示公式##STR3## 中的一个,R表示氢或基团--CN,--CHO,--CH.dbd.NOH,--CONH.sub.2或--COOR.sub.1,R.sub.1表示基团(C.sub.1-C.sub.4)-烷基,n表示整数3、4或5,并提供了它们的制备方法、药物制剂以及它们用于治疗可以通过激活膜K.sup.+通道治愈的疾病,如高血压和哮喘。
    公开号:
    US05077307A1
点击查看最新优质反应信息

文献信息

  • Substituted thienopyrans as antihypertensive agents
    申请人:Ortho Pharmaceutical Corporation
    公开号:US04992435A1
    公开(公告)日:1991-02-12
    Substituted thienopyrans and processes for preparing the thienopyrans are disclosed. The thienopyrans are useful as antihypertensive agents; antianginals are peripheral antivasoconstrictive agents.
    本发明涉及替代噻吩并制备噻吩并的方法。这些噻吩并可用作降压药物;抗心绞痛药物和外周抗血管收缩药物。
  • Process for the preparation of enantiomerically pure thienopyran
    申请人:Ortho Pharmaceutical Corporation
    公开号:US05457212A1
    公开(公告)日:1995-10-10
    A process for the preparation of enantiomerically pure thienopyran derivatives of the formula ##STR1## is described. The thienopyran derivatives are relaxants of smooth muscle tone and as such are useful in vascular tissue for the treatment of hypertension disease, angina and other vascular disorders characterized by poor regional perfusion.
    描述了一种制备配体纯度噻吩吡喃衍生物的过程,其化学式为##STR1##。这些噻吩吡喃衍生物是平滑肌张力松弛剂,因此在血管组织中对治疗高血压疾病、心绞痛和其他因局部灌注不良而表现出的血管疾病中很有用。
  • Substituted thienopyrans
    申请人:Ortho Pharmaceutical Corporation
    公开号:US05030736A1
    公开(公告)日:1991-07-09
    Substituted thienopyrans and processes for preparing the thienopyrans are disclosed. The thienopyrans are useful as antihypertensive agents; antianginals are peripheral antivasoconstrictive agents.
    本发明揭示了替代噻吩并制备噻吩的过程。这些噻吩可用作降压剂;抗心绞痛和外周抗血管收缩剂。
  • The process for the preparation of enantiomerically pure thienopyran derivative
    申请人:ORTHO PHARMACEUTICAL CORPORATION
    公开号:EP0493048A1
    公开(公告)日:1992-07-01
    A process for the preparation of enantiomerically pure thienopyran derivatives of the formula is described. The thienopyran derivatives are relaxants of smooth muscle tone and as such are useful in vascular tissue for the treatment of hypertension disease, angina and other vascular disorders characterized by poor regional perfusion.
    一种制备对映体纯的式噻吩并吡喃衍生物的工艺 的对映体纯噻喃衍生物的制备方法。噻喃衍生物是平滑肌张力的松弛剂,因此可用于血管组织,治疗高血压病、心绞痛和其他以区域灌注不良为特征的血管疾病。
  • Thiophene systems. 16. Interesting contrasts in electrocyclic reactions for thieno[3,2-b]- and -[2,3-b]pyrans with chromenes
    作者:Ignatius J. Turchi、Jeffery B. Press、James J. McNally、Mary Pat Bonner、Kirk L. Sorgi
    DOI:10.1021/jo00069a026
    日期:1993.8
    Thienopyrans 3, 4, and 5 were synthesized and found to have remarkable differences in stability. Systems 3 and 5 undergo electrocyclic ring-opening to 8 and 18, respectively. In acid milieu at room temperature, system 5 exists in an equilibrium with ring-opened thienopyranone 18. Ground state and activation parameters for the open and closed forms of thienopyrans 3 and 5 as well as the isosteric chromene 2 were calculated using the AM1 Hamiltonian. The Gibbs' free energy differences between the open and closed isomers in each system were found to be predictive of the observed equilibria. The mechanism for ring-opening in both thienopyran systems is proposed to be acid-catalyzed based on the calculated temperatures required for ring-opening as well as experimentally determined results.
查看更多

同类化合物

化合物SEP-363856HYDROCHLORIDE 6,7-二氢-4H-噻吩并[3,2-c]吡喃-4-甲胺 6,7-二氢-4H-噻吩并[3,2-c]吡喃-2-羧酸乙酯 6,7-二氢-4H-噻吩并[3,2-c]吡喃-2-羧酸 5,7-二氢-4H-噻吩并[2,3-c]吡喃-3-羧酸 5,7-二氢-4H-噻吩并[2,3-C]吡喃-3-羧酸乙酯 4-(2-羟基乙基)-4-甲基-6,7-二氢-4h-噻吩并[3,2-c]吡喃 4,5-二氢螺[哌啶-4,7-噻吩并[2,3-c]吡喃] 4',5'-二氢-螺[哌啶-4,7'-[7H]噻吩并[2,3-c]吡喃]-1-羧酸叔丁酯 2-氯-4,5-二氢螺[哌啶-4,7-噻吩并[2,3-c]吡喃] 2-氨基-5,5-二甲基-4,7-二氢-5H-噻吩并[2,3-C]吡喃-3-羧酸叔丁酯 2-氨基-4,7-二氢-5H-噻吩并[2,3-c]吡喃-3-羧酸乙酯 2-氨基-4,7-二氢-5H-噻吩并[2,3-c]吡喃-3-甲腈 2-[[(苯甲酰基氨基)硫代甲酰]氨基]-4,7-二氢-5,5-二甲基-5H-噻吩并[2,3-C]吡喃-3-羧酸 (4-甲基-6,7-二氢-4H-噻吩并[3,2-c]吡喃-4-基)乙酸 (2-羧基噻吩-3-基)乙酸酐 2-(3-hydroxy-2,2-dimethylpropanamido)-5,5,7,7-tetramethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-3-carboxamide 2-[[(2S)-2-hydroxy-3,3-dimethylbutanoyl]amino]-5,5,7,7-tetramethyl-4H-thieno[2,3-c]pyran-3-carboxamide N-(3-carbamoyl-5,5,7,7-tetramethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-2-yl)-4-chloro-5-methyl-1H-pyrazole-3-carboxamide N-(3-carbamoyl-5,5,7,7-tetramethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-2-yl)-2-fluoronicotinamide N-(3-carbamoyl-5,5,7,7-tetramethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-2-yl)-2-oxopyrrolidine-3-carboxamide 2-(1-(hydroxymethyl)cyclopropanecarboxamido)-5,5,7,7-tetramethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-3-carboxamide N-(3-carbamoyl-5,5,7,7-tetramethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-2-yl)-1H-pyrazole-5-carboxamide tert-butyl 2-(3-(3,4-dimethoxyphenyl)thioureido)-5,7-dihydro-4H-thieno[2,3-c]pyran-3-carboxylate trans-6-(benzyloxy)-2-carbamoyl-5,6-dihydro-5,5-dimethyl-7-(2-oxopiperidin-1-yl)-5H-thieno<3,2-b>pyran trans-6-(benzyloxy)-2-carbomethoxy-5,6-dihydro-5,5-dimethyl-7-(2-oxopiperidin-1-yl)-5H-thieno<3,2-b>pyran trans-6-(benzyloxy)-2-cyano-5,6-dihydro-5,5-dimethyl-7-(2-oxopiperidin-1-yl)-5H-thieno<3,2-b>pyran trans-5,6-dihydro-6-hydroxy-5,5-dimethyl-7-(2-oxopiperidin-1-yl)-5H-thieno<3,2-b>pyran trans-6-(benzyloxy)-2-bromo-5,6-dihydro-5,5-dimethyl-7-(2-oxopiperidin-1-yl)-5H-thieno<3,2-b>pyran trans-2-bromo-5,6-dihydro-6-hydroxy-5,5-dimethyl-7-(2-oxopiperidin-1-yl)-5H-thieno<3,2-b>pyran (-)-trans-5,6-dihydro-6-hydroxy-5,5-dimethyl-7-(2-oxopiperidin-1-yl)-5H-thieno<3,2-b>pyran 5,5-dimethyl-2-nitro-7-(2-oxopiperidin-1-yl)-5H-thieno<3,2-b>pyran trans-2-cyano-5,6-dihydro-6-hydroxy-5,5-dimethyl-7-(2-oxopiperidin-1-yl)-5H-thieno<3,2-b>pyran (-)-trans-5,6-dihydro-6-hydroxy-5,5-dimethyl-2-nitro-7-(2-oxopiperidin-1-yl)-5H-thieno<3,2-b>pyran trans-5,6-dihydro-6-hydroxy-5,5-dimethyl-2-nitro-7-(2-oxopiperidin-1-yl)-5H-thieno<3,2-b>pyran cis-7-amino-5,6-dihydro-6-hydroxy-5,5-dimethyl-5H-thieno<3,2-b>pyran 2-[3-(3-trifluoromethyl[1,2,4]oxadiazol-5-yl)-4,7-dihydro-5H-thieno[2,3-c]pyran-2-ylcarbamoyl]cyclopent-1-enecarboxylic acid 2-[3-(4-trifluoromethylthiazol-2-yl)-4,7-dihydro-5H-thieno[2,3-c]pyran-2-ylcarbamoyl]cyclopent-1-enecarboxylic acid 2-[3-(4,5-dimethyloxazol-2-yl)-4,7-dihydro-5H-thieno[2,3-c]pyran-2-ylcarbamoyl]cyclopent-1-enecarboxylic acid 4,4-dimethyl-6,7-dihydro-4H-thieno[3,2-c]pyran 1,1-(3-dimethylamino-3-phenyl-methylene)-3,4-dihydro-1H-2-oxa-9-thia-fluoren N,N-dimethyl-N-{4-phenyl-spiro[cyclohexane-1,4'-1,4'-dihydro-2'H-3'-oxa-9'-thiafluoren]-4-yl}amine triflate N,N-dimethyl-N-{4-phenyl-spiro[cyclohexane-1,4'-1,4'-dihydro-2'H-3'-oxa-9'-thiafluoren]-4-yl}amine trans-5,6-dihydro-6-hydroxy-2,5,5-trimethyl-7-(2-oxopyrrolidin-1-yl)-5H-thieno<3,2-b>pyran trans-2-bromo-5,6-dihydro-6-hydroxy-5,5-dimethyl-7-(2-oxopyrrolidin-1-yl)-5H-thieno<3,2-b>pyran 5-Cyclohexyl-7-oxo-5-phenyl-7H-thieno[3,2-b]pyran-3-carboxylic acid tert-butyl 2-amino-5,7-dihydro-4H-thieno[2,3-c]pyran-3-carboxylate N-(3-carbamoyl-5,5,7,7-tetramethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-2-yl)-5-methyl-1H-pyrazole-3-carboxamide 5,5-Dimethyl-7-(2-oxo-1-pyrrolidinyl)-5H-thieno[3,2-b]pyran-2-carbonitrile 5,5-Dimethyl-7-(2-oxo-1-pyrrolidinyl)-2-(thiazolin-2-yl)-5-thieno[3,2-b]pyran